progressive supranuclear palsy
Conditions
Interventions
Index test:disease-specific brain metabolic patterns,tau deposition patterns
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients with progressive supranuclear palsy (PSP): 1. Citizens of the People's Republic of China, male or female, aged between 40 and 85 years old. 2. Clinical diagnosed progressive supranuclear palsy at the first visit; meet the International Movement Disorders Society (MDS) diagnostic criteria for PSP (2017 version) and the Chinese clinical diagnostic criteria for PSP palsy (2016 version). The clinical diagnosis should be made independently by two movement disorder specialists from the Department of Neurology, Huashan Hospital, and the further diagnosis information (suggestive of PSP (SoPSP) or possible PSP (possible PSP) or probable PSP (probable PSP)) should be offered. Patients with disputes about the diagnosis will be decided through collective discussion by the movement disorder professional group of the Department of Neurology, Huashan Hospital. However, in the follow-up research process, the diagnostic criteria recommended tau protein-related pathological examinations should be carried out, and necessary diagnostic confirmation or diagnostic changes should be carried out. 3. Disease symptoms and severity. The subjects recruited in this study need to have the basic diagnostic features of PSP. For the specific symptom spectrum, refer to the symptoms in the diagnostic criteria. As for severity, the patient should be able to walk independently with the help of additional objects at the first visit (H&Y = 4). 4. Before any evaluation, the subjects or their legal representatives understand and sign the written informed consent. Inclusion criteria for patients with Parkinson's disease: 1. Age between 45 and 80; gender is not limited. 2. Patients meet the diagnostic criteria for Parkinson's disease (MDS 2015). 3. H&Y between 1 and 3 (inclusive). 4. Brain MRI has no evidence of other neurological diseases. 5. If relevant drugs that improve the clinical symptoms of PD have been used, the study can only be started after the drug has been maintained at a stable dose for more than 30 days. 6. Before any evaluation, the subjects or their legal representatives understand and sign the written informed consent. If necessary, the subject can be accompanied by the subject by a nursing staff. Inclusion criteria for patients with multiple system atrophy: 1. Age between 45 and 80; gender is not limited. 2. Patients meet the diagnostic criteria for multiple system atrophy (Gilman criteria, Neurology 2008). 3. H&Y between 1 and 3 (inclusive). 4. Brain MRI has no evidence of other neurological diseases. 5. If relevant drugs that improve clinical symptoms have been used, the study can only be started after the drug has been maintained at a stable dose for more than 30 days. 6. Before any evaluation, the subjects or their legal representatives understand and sign the written informed consent. If necessary, the subject can be accompanied by the subject by a nursing staff. Inclusion criteria for non-disease controls: 1. Age between 45 and 80; gender is not limited. 2. The researchers have determined that the motor function is normal through exercise tests. UPDRS motor score is 0 points. 3. No nervous system disease, major chronic disease, malignant tumor or acute infectious disease confirmed by the investigator. 4. No family history of parkinsonism, no family history of neurological diseases related to cognitive impairment and movement disorders. 5. Understand and sign a written informed consent form prior to any assessmen
Exclusion criteria
Exclusion criteria: 1. Obvious mental symptoms or severe depression. 2. Patients with obvious cognitive impairment (MMSE<20 points). 3. Severe loss of postural reflexes (inability to stand and walk independently). 4. Relying on feeding tube for feeding. 5. Women of childbearing age who were pregnant at the time of enrollment. 6. Have a clear history of brain diseases (clear history of stroke, traumatic brain injury, brain tumor history, hydrocephalus) 7. Those with serious heart, liver, kidney and other medical diseases. 8. Other circumstances that the researcher thinks he is not suitable to participate in this study. 9. Participants in other clinical trials during the same period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brain Glucose Metabolism Imaging;Accuracy, specificity, sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Brain tau imaging; | — |
Countries
China
Contacts
Public ContactChuantao Zuo
Huashan Hospital, Fudan University
Outcome results
None listed